, Columnist
Regeneron's Delivery Isn't Matching the Hype
Wall Street expects home runs, but new Dupixent data is another hiccup.
This article is for subscribers only.
The problem with sky-high expectations is that you have to meet them.
Regeneron Pharmaceuticals Inc. and its partner Sanofi on Monday released trial data for their drug Dupixent in treating severe asthma that, while likely good enough to net an FDA approval, fell short enough of very high hopes to send Regeneron shares down 5 percent.